智通财经APP获悉，3月12日，CDE官网显示，艾伯维(ABBV.US)乌帕替尼缓释片的一项新适应症拟纳入优先审评，拟用于治疗成人和12岁及以上青少年的非节段型白癜风。乌帕替尼(Upadacitinib)是一种选择性JAK抑制剂，同时也是艾伯维旗下的重磅产品，2025年全球销售额为83.04亿美元(+39.07%)。

截图来源：CDE官网

本次优先审评的申请针对的是一项新适应症：成人和12岁及以上青少年的非节段型白癜风。关于该适应症，就在今年2月，艾伯维宣布，已向美国FDA和欧洲EMA提交了乌帕替尼用于治疗成人和青少年非节段型白癜风(NSV)的新适应症申请。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.